Advertisement
A vs HSDT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and HSDT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileHSDT’s FA Score has 0 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- HSDT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while HSDT’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 4 bearish.
- HSDT’s TA Score: 4 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а +0.71% price change this week, while HSDT (@Investment Managers) price change was -40.11% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.18%. For the same industry, the average monthly price growth was +2.67%, and the average quarterly price growth was +52.37%.
The average weekly price growth across all stocks in the @Investment Managers industry was +0.47%. For the same industry, the average monthly price growth was -1.77%, and the average quarterly price growth was +18.50%.
Reported Earning Dates
A is expected to report earnings on Dec 01, 2025.
Industries' Descriptions
@Medical Specialties (-0.18% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Investment Managers (+0.47% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
| A | HSDT | A / HSDT | |
| Capitalization | 40.2B | 407M | 9,877% |
| EBITDA | 1.8B | -22.74M | -7,902% |
| Gain YTD | 5.689 | -97.989 | -6% |
| P/E Ratio | 33.16 | N/A | - |
| Revenue | 6.79B | 295K | 2,301,017% |
| Total Cash | 1.54B | 6.08M | 25,255% |
| Total Debt | 3.41B | 0 | - |
A | HSDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 59 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 56 | 91 | |
P/E GROWTH RATING 1..100 | 30 | 100 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (19) in the Biotechnology industry is significantly better than the same rating for HSDT (91) in the Medical Specialties industry. This means that A’s stock grew significantly faster than HSDT’s over the last 12 months.
A's Profit vs Risk Rating (59) in the Biotechnology industry is somewhat better than the same rating for HSDT (100) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than HSDT’s over the last 12 months.
A's SMR Rating (100) in the Biotechnology industry is in the same range as HSDT (100) in the Medical Specialties industry. This means that A’s stock grew similarly to HSDT’s over the last 12 months.
A's Price Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for HSDT (91) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than HSDT’s over the last 12 months.
A's P/E Growth Rating (30) in the Biotechnology industry is significantly better than the same rating for HSDT (100) in the Medical Specialties industry. This means that A’s stock grew significantly faster than HSDT’s over the last 12 months.
| A | HSDT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 47% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 60% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 67% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 61% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 61% | 16 days ago 81% |
| Declines ODDS (%) | 8 days ago 60% | 8 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 56% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 82% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NVDL | 87.94 | 1.80 | +2.09% |
| GraniteShares 2x Long NVDA Daily ETF | |||
| EMMF | 30.97 | 0.20 | +0.66% |
| WisdomTree Emerging Markets Mltfctr | |||
| EWJV | 38.88 | 0.15 | +0.39% |
| iShares MSCI Japan Value ETF | |||
| RZB | 24.93 | 0.05 | +0.20% |
| Reinsurance Group of America | |||
| GDOC | 33.15 | N/A | N/A |
| Goldman Sachs Future Health Care Eq ETF | |||
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
HSDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, HSDT has been loosely correlated with MLCI. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if HSDT jumps, then MLCI could also see price increases.
| Ticker / NAME | Correlation To HSDT | 1D Price Change % | ||
|---|---|---|---|---|
| HSDT | 100% | -36.49% | ||
| MLCI - HSDT | 41% Loosely correlated | -0.67% | ||
| STSS - HSDT | 36% Loosely correlated | -9.32% | ||
| HSCS - HSDT | 32% Poorly correlated | -2.99% | ||
| A - HSDT | 24% Poorly correlated | +1.04% | ||
| STE - HSDT | 24% Poorly correlated | +1.50% | ||
More | ||||